FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

106 letters match. Newest first.

  1. GenoGenix LLC

    FDA warns GenoGenix over insanitary sterile compounding, endotoxin-contaminated NAD+, and unapproved drugs.

    High risk
  2. Boothwyn Pharmacy, LLC

    Boothwyn Pharmacy made sterile drugs in insanitary conditions and shipped lots that failed sterility and potency tests.

    High risk
  3. Palamur Biosciences Private Limited

    FDA warns Palamur Biosciences over GLP violations in medical device safety testing and inadequate corrective actions.

    High risk
  4. Darmerica, LLC

    FDA warns Darmerica over manufacturing-quality violations and mislabeled drug ingredients, including retatrutide.

    High risk
  5. FWD Care, Inc. dba FWD

    FDA warned telehealth company FWD Care that its website claims for compounded semaglutide and tirzepatide drugs are false or misleading.

    Medium
  6. Expert Aesthetics

    FDA warned Expert Aesthetics over website claims that its compounded semaglutide and tirzepatide are generic Ozempic and Mounjaro.

    Low
  7. Healthy Living Clinic

    FDA warned Healthy Living Clinic that its website misbrands compounded semaglutide by comparing it to Wegovy, Ozempic, and Rybelsus.

    Low
  8. Hims & Hers Health, Inc. dba Hers

    FDA warned Hims & Hers (Hers) that its website misleads consumers about compounded semaglutide by implying it is the same as approved Ozempic and Wegovy.

    Medium
  9. Amazing Meds

    FDA warned online seller Amazing Meds over unapproved compounded retatrutide and a misleading "same as Ozempic/Wegovy" semaglutide claim.

    High risk
  10. GenLabMeds

    GenLabMeds offered compounded retatrutide, semaglutide and tirzepatide online as unapproved, misbranded drugs with false or misleading claims.

    High risk
  11. FitRX, LLC dba Zealthy

    FDA warns Zealthy over website claims that compounded semaglutide is the same as Wegovy and Ozempic.

    Medium
  12. Lovely Meds, Inc. dba Lovely Meds

    FDA cited Lovely Meds for misleading website claims that compounded semaglutide and tirzepatide are the same as FDA-approved drugs.

    Low
  13. The HCG Institute

    FDA warns The HCG Institute over misleading claims for compounded semaglutide sold online.

    High risk
  14. Vitals RX

    FDA warned telehealth seller Vitals RX that its website falsely implies compounded semaglutide and tirzepatide are the approved drug Ozempic.

    Medium
  15. Tuyo Health, Inc. dba Tuyo Health

    FDA warns Tuyo Health over misleading claims for compounded semaglutide and tirzepatide sold online.

    Medium
  16. JulyMD

    FDA warned JulyMD that its website sold compounded semaglutide with misleading claims comparing it to Wegovy and Ozempic.

    High risk
  17. Slendid

    FDA warned Slendid that its website sells compounded semaglutide and tirzepatide with a false "clinically proven" claim, making the drugs misbranded.

    Medium
  18. Sprout Health Partners LLC dba Sprout Health

    FDA warned telehealth seller Sprout Health that its website's claim compounded semaglutide and tirzepatide are FDA-approved makes the drugs misbranded.

    Low
  19. Master Pharmaceuticals Group

    FDA warned Master Pharmaceuticals Group that its website sold compounded semaglutide and tirzepatide with false or misleading claims.

    High risk
  20. TRYM Health, Inc. dba TRYM Health

    FDA told telehealth seller TRYM Health its website claims for compounded semaglutide and tirzepatide are false and misleading, making the drugs misbranded.

    Medium
  21. inspire.clinic

    FDA warned telehealth site inspire.clinic that claims its compounded semaglutide and tirzepatide are similar to Ozempic or Mounjaro misbrand the drugs.

    Low
  22. Bioverse, Inc. dba Bioverse

    FDA warned Bioverse that its website made false or misleading claims for compounded semaglutide and tirzepatide drugs.

    Low
  23. Elevate Your Wellness LLC, dba Elevated

    FDA warned Elevated that its website offered compounded semaglutide and tirzepatide with misleading claims they match FDA-approved drugs.

    Low
  24. Cosmo Medical Spa dba Cosmo Med Spa

    FDA warned Cosmo Med Spa over its website selling compounded semaglutide with claims implying it is FDA-approved Ozempic.

    Medium
  25. directmeds.com, Inc. dba DirectMeds

    FDA warned DirectMeds that its website sold compounded semaglutide and tirzepatide with false or misleading claims implying they match FDA-approved drugs.

    High risk
  26. MedClub by Dr. Jenn

    FDA warns MedClub by Dr. Jenn over unapproved compounded retatrutide and misleading semaglutide claims on its website.

    High risk
  27. Mane & Steel, LLC. dba Mane & Steel

    FDA warns Mane & Steel over false 'clinically proven' claims for compounded semaglutide.

    Low
  28. Lumimeds

    FDA warns Lumimeds over website claims implying its compounded semaglutide and tirzepatide are FDA-approved.

    High risk
  29. GLP-1 Solution

    GLP-1 Solution sells unapproved compounded retatrutide online and misleadingly compares semaglutide and tirzepatide to FDA-approved brand drugs.

    High risk
  30. Body Good Studio

    FDA warned Body Good Studio over its website selling compounded semaglutide with a false claim that it matches Ozempic and Wegovy.

    High risk
  31. All American Wellness

    FDA warned telehealth seller All American Wellness that its website wrongly compares compounded semaglutide and tirzepatide to Ozempic and Mounjaro.

    Low
  32. Healthy Male

    FDA warns Healthy Male that its website sells compounded tirzepatide with false or misleading 'clinically proven' weight-loss claims.

    Low
  33. Intimate Rose

    FDA warned Intimate Rose that its website sells compounded semaglutide and tirzepatide with misleading claims that they match approved drugs.

    High risk
  34. Curex

    FDA warned Curex that its website ads for compounded semaglutide and tirzepatide are false or misleading.

    High risk
  35. Healthon Inc. dba Healthon

    FDA warned Healthon over unapproved compounded semaglutide and tirzepatide sold online with false 'FDA-approved' and 'same as' claims.

    High risk
  36. Eli Lilly and Company

    FDA says Eli Lilly’s Oprah-linked video for Zepbound and Mounjaro misled on serious risks.

    High risk
  37. Novo Nordisk Inc.

    FDA says Novo Nordisk’s Oprah Winfrey video makes Wegovy, Ozempic and Victoza look safer than their labels allow.

    High risk
  38. Eli Lilly and Company

    FDA says Eli Lilly's Zepbound online video omitted risk and limitations information and was not submitted to FDA.

    High risk
  39. Eli Lilly and Company

    FDA says Eli Lilly's sponsored Zepbound video omitted risk and use information, misbranding the drug.

    Low
  40. Jiangsu Kerbio Medical Technology Group Co.

    FDA cites Jiangsu Kerbio Medical Technology Group for serious GLP violations in medical device safety testing.

    High risk
  41. CCIC Huatongwei International Inspection Co., Ltd.

    FDA warns CCIC Huatongwei after inspection found copied data and missing records in medical device safety tests.

    High risk
  42. USApeptide.com

    FDA warns Germany-based USApeptide.com that it sells unapproved and misbranded semaglutide and tirzepatide drugs to U.S. consumers online.

    High risk
  43. Prime Vitality, Inc. dba Prime Peptides

    FDA warned Prime Peptides that its website sells Semaglutide and Retatrutide as unapproved new drugs for weight loss and diabetes.

    High risk
  44. Swisschems

    Swisschems sells Semaglutide and Retatrutide as unapproved new drugs despite research-chemical labeling.

    High risk
  45. Xcel Research LLC

    FDA warned Xcel Research for selling unapproved peptide drugs online with human-use claims.

    High risk
  46. Summit Research Peptides

    FDA warned Summit Research Peptides for selling unapproved semaglutide, retatrutide, cagrilintide, tirzepatide, and mazdutide with drug claims.

    High risk
  47. Veronvy

    FDA warned Veronvy that its Elily Veronvy weight-loss drops are unapproved new drugs and falsely labeled "FDA APPROVED."

    Medium
  48. Nomida.biz

    FDA warned Nomida.biz over its website selling unapproved and misbranded semaglutide and tirzepatide drugs to U.S. consumers.

    High risk
  49. Mid-Link Testing Company, Ltd

    FDA warns Mid-Link Testing over unreliable Good Laboratory Practice (GLP) safety data for medical device tests.

    High risk
  50. Sanitation & Environmental Technology Institute dba SDWH

    FDA found GLP violations in SDWH's nonclinical testing of medical devices, raising doubts about safety data.

    High risk